Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells 10,000 Shares of Stock
Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells 10,000 Shares of Stock
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) CEO Helen Torley sold 10,000 shares of the company's stock in a transaction on Thursday, January 19th. The stock was sold at an average price of $52.41, for a total value of $524,100.00. Following the sale, the chief executive officer now directly owns 587,177 shares in the company, valued at approximately $30,773,946.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Halozyme治疗公司(纳斯达克:Halo-Get评级)首席执行官海伦·托利在1月19日(星期四)的一笔交易中出售了10,000股该公司股票。这只股票的平均售价为52.41美元,总价值为524,100.00美元。出售后,首席执行官现在直接拥有公司587,177股,价值约30,773,946.57美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在美国证券交易委员会网站.
Helen Torley also recently made the following trade(s):
海伦·托利最近还做了以下交易:
- On Thursday, December 15th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $57.37, for a total value of $573,700.00.
- On Thursday, November 17th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $52.15, for a total value of $521,500.00.
- 12月15日,星期四,海伦·托利出售了10,000股Halozyme Treateutics股票。这只股票的平均售价为57.37美元,总价值为573,700.00美元。
- 11月17日,星期四,海伦·托利出售了10,000股Halozyme Treateutics股票。这些股票的平均价格为52.15美元,总价值为521,500.00美元。
Halozyme Therapeutics Stock Down 2.6 %
Halozyme治疗类股下跌2.6%
Shares of HALO stock traded down $1.35 on Thursday, reaching $51.32. 1,327,579 shares of the stock were exchanged, compared to its average volume of 1,563,240. The company has a current ratio of 5.97, a quick ratio of 5.03 and a debt-to-equity ratio of 15.37. The business's 50 day moving average price is $55.40 and its 200 day moving average price is $48.23. The company has a market capitalization of $6.94 billion, a price-to-earnings ratio of 35.35, a PEG ratio of 0.65 and a beta of 1.23. Halozyme Therapeutics, Inc. has a twelve month low of $31.36 and a twelve month high of $59.46.
光环股票周四下跌1.35美元,至51.32美元。该股成交量为1,327,579股,而平均成交量为1,563,240股。该公司的流动比率为5.97,速动比率为5.03,债务权益比率为15.37。该业务的50日移动均线价格为55.40美元,其200日移动均线价格为48.23美元。该公司市值为69.4亿美元,市盈率为35.35倍,聚乙二醇率为0.65倍,贝塔系数为1.23。Halozyme治疗公司的12个月低点为31.36美元,12个月高位为59.46美元。
Hedge Funds Weigh In On Halozyme Therapeutics
对冲基金入股Halozyme Treeutics
Large investors have recently bought and sold shares of the stock. Financial Gravity Asset Management Inc. acquired a new position in Halozyme Therapeutics in the third quarter valued at $2,220,000. First Horizon Advisors Inc. boosted its stake in Halozyme Therapeutics by 188.8% in the second quarter. First Horizon Advisors Inc. now owns 722 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 472 shares in the last quarter. Meeder Asset Management Inc. raised its holdings in shares of Halozyme Therapeutics by 223.6% in the second quarter. Meeder Asset Management Inc. now owns 741 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 512 shares during the last quarter. Brown Brothers Harriman & Co. purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $35,000. Finally, Selective Wealth Management Inc. purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $44,000. Institutional investors and hedge funds own 96.32% of the company's stock.
大型投资者最近买卖了该股的股票。金融重力资产管理公司在第三季度收购了Halozyme治疗公司的一个新头寸,价值222万美元。First Horizon Advisors Inc.在第二季度将其在Halozyme Treateutics的持股增加了188.8%。First Horizon Advisors Inc.现在持有这家生物制药公司722股股票,价值3.2万美元,该公司在上个季度增持了472股股票。Meeder Asset Management Inc.在第二季度将其持有的Halozyme Treateutics股票增加了223.6%。Meeder Asset Management Inc.现在持有这家生物制药公司741股股票,价值3.3万美元,该公司在上个季度又购买了512股。布朗兄弟哈里曼公司在第二季度购买了Halozyme Treateutics的新股份,价值约3.5万美元。最后,选择性财富管理公司在第二季度购买了Halozyme Treateutics的新股份,价值约44,000美元。机构投资者和对冲基金持有该公司96.32%的股票。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
HALO has been the subject of a number of analyst reports. SVB Leerink lowered their price objective on Halozyme Therapeutics from $62.00 to $61.00 and set an "outperform" rating for the company in a research report on Wednesday, January 11th. Wells Fargo & Company initiated coverage on shares of Halozyme Therapeutics in a research report on Monday, November 28th. They issued an "overweight" rating and a $65.00 price objective on the stock. Benchmark lifted their price objective on shares of Halozyme Therapeutics from $55.00 to $68.00 and gave the stock a "buy" rating in a research report on Thursday, December 8th. JPMorgan Chase & Co. boosted their target price on shares of Halozyme Therapeutics from $53.00 to $54.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 22nd. Finally, JMP Securities boosted their target price on shares of Halozyme Therapeutics from $60.00 to $62.00 and gave the stock a "market outperform" rating in a research note on Wednesday, November 9th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $59.63.
光环已经成为了许多分析师报告的主题。SVB Leerink在1月11日星期三的一份研究报告中将Halozyme Treateutics的目标价从62.00美元下调至61.00美元,并为该公司设定了“跑赢大盘”的评级。富国银行公司在11月28日星期一的一份研究报告中开始了对Halozyme治疗公司股票的报道。他们对该股的评级为“增持”,目标价为65.00美元。基准将Halozyme治疗公司的股票目标价从55.00美元上调至68.00美元,并在12月8日星期四的一份研究报告中给予该股“买入”评级。11月22日,摩根大通将Halozyme治疗公司的股票目标价从53.00美元上调至54.00美元,并在周二的一份研究报告中给予该股“增持”评级。最后,JMP证券将Halozyme Treeutics的股票目标价从60.00美元上调至62.00美元,并在11月9日星期三的一份研究报告中给出了该股的“市场表现优于大盘”的评级。一位股票研究分析师对该股的评级为持有,七位分析师对该公司的评级为买入。根据MarketBeat.com的数据,该公司目前的平均评级为“中等买入”,平均目标价为59.63美元.
About Halozyme Therapeutics
关于Halozyme治疗药物
(Get Rating)
(获取评级)
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Halozyme治疗公司在美国、瑞士、爱尔兰、比利时、日本和国际上作为生物制药技术平台公司运营。该公司的产品基于Enhanze药物输送技术,这是一种获得专利的重组人透明质酸酶(RHuPH20),使可注射生物制剂(如单抗和其他治疗分子)以及小分子和液体能够在皮下输送。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Halozyme Therapeutics (HALO)
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
- 免费获取StockNews.com关于Halozyme治疗的研究报告(Halo)
- 高股息率的必和必拓认为中国推动了23年的增长
- 爱彼迎的涨幅是否会像分析师预测的那样达到38%?
- 特斯拉汽车降价是否意味着特斯拉股票也会降价?
- 微软的裁员标志着其他科技公司的裁员?
- 快速购买Fastenal的原因不止一个
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Halozyme治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Halozyme治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。